Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Idorsia. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Idorsia's earnings available for a low price, and how does
this compare to other companies in the same industry?
Idorsia is not considered high growth as it is expected to be loss making for the next 1-3 years.
Idorsia's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Idorsia's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. Mr. Clozel serves as the Chief Executive Officer of Idorsia Ltd, a wholly-owned subsidiary of Actelion Ltd. He was a Practicing Cardiologist for 11 years, from 1974 to 1985. He served as the Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche for 12 years, from 1985 to 1997. He serves as a Director of Actelion Pharmaceuticals Ltd and Idorsia Ltd. He served as a Director of Actelion Ltd until June 16, 2017. He served as a Professor to the Chairman of Technical Innovation - Liliane Bettencourt at College de France, Paris, France for one year. Mr. Clozel holds a Medical Degree in France and obtained further training in Pharmacology and Physiology at the University of Montreal, Canada and the University of California, San Francisco.
Insufficient data for Jean-Paul to compare compensation growth.
Insufficient data for Jean-Paul to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
CEO & Director
Executive VP & CFO
Executive VP & Chief Scientific Officer
Senior VP and Head of Investor Relations & Corporate Communications
Executive VP & Head of Global Clinical Development
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Idorsia board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company has collaboration agreements with Johnson & Johnson to jointly develop and commercialize aprocitentan and its derivative compounds or products; Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy; and collaboration agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.